Envoy Medical, Inc. (COCH)
$
1.37
+0.06 (4.38%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Envoy Medical, Inc. specializes in medical technologies targeting the spectrum of hearing loss, providing an array of products including hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. The company recorded an operating income of -$18,514,000.00 reflecting its earnings from core operations. The gross profit stands at $225,000.00 highlighting the company's profitability from core operations. Additionally, the company reported depreciation and amortization expenses of $0.00 illustrating the wear and tear of its assets. The net total of other income and expenses is -$2,281,000.00 reflecting non-core financial activities. Furthermore, the weighted average number of shares outstanding is $18,790,448,000.00 emphasizing the company's shareholder base. In the financial market, the stock is affordable at $1.39 making it suitable for budget-conscious investors. However, the stock shows a low average trading volume of $25,596.00 indicating lower market activity. With a market capitalization of $29,172,643.00 the company is classified as a small-cap player. Envoy Medical, Inc. is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth through its advancements in hearing health technologies.
Is Envoy Medical, Inc. (COCH) a good investment?
Investing in Envoy Medical, Inc. (COCH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Envoy Medical, Inc. (COCH)'s stock forecast?
Analysts predict Envoy Medical, Inc. stock to fluctuate between $1.21 (low) and $7.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Envoy Medical, Inc.'s market capitalization?
As of 2025-04-03, Envoy Medical, Inc.'s market cap is $29,172,643, based on 21,293,900 outstanding shares.
How does Envoy Medical, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Envoy Medical, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Envoy Medical, Inc. (COCH) stock?
To buy Envoy Medical, Inc. (COCH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for COCH. Place an order (Market, Limit, etc.).
What is the best time to invest in Envoy Medical, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Envoy Medical, Inc. perform in the last earnings report?
Revenue: $225,000 | EPS: -$0.00 | Growth: -99.95%.
Where can I find Envoy Medical, Inc.'s investor relations reports?
Visit https://www.envoymedical.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Envoy Medical, Inc.?
You can explore historical data from here
What is the all-time high and low for Envoy Medical, Inc. stock?
All-time high: $11.46 (2024-03-07) | All-time low: $0.75 (2023-11-17).
What are the key trends affecting Envoy Medical, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
newsfilecorp.com
4 days ago
Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear Implant White Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events. Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025.
newsfilecorp.com
18 days ago
Seek to clarify that certain hearing implants are prosthetics and therefore not subject to the hearing aid coverage exclusion, allowing for potential Medicare coverage White Bear Lake, Minnesota--(Newsfile Corp. - March 17, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced the reintroduction of the Hearing Device Coverage Clarification Act in both the U.S. House of Representatives and U.S. Senate. Representative Michelle Fischbach (R-MN) reintroduced the House version of the bill - H.R.
newsfilecorp.com
23 days ago
Billionaire Entrepreneur Glen Taylor, the Company's Largest Shareholder, Continues to Invest Significant Capital into the Company Furthering Its Progress White Bear Lake, Minnesota--(Newsfile Corp. - March 12, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced securing $10 Million in financing from its largest existing shareholder, billionaire entrepreneur Glen Taylor. The financing provides the Company with access to additional capital during what it expects to be a transformative year with several important milestones.
newsfilecorp.com
25 days ago
White Bear Lake, Minnesota--(Newsfile Corp. - March 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced that it will participate in the 37th Annual ROTH Conference being held on March 16 - 18, 2025 at the Laguna Cliffs Marriott Resort and Spa in Dana Point, California. Brent Lucas, Chief Executive Officer, and David R.
newsfilecorp.com
a month ago
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on providing hearing loss sufferers with innovative solutions today announces the successful enrollment of the first two participants in its pivotal clinical study. The purpose of the study is to investigate the safety and efficacy of the fully implanted Acclaim® cochlear implant and support its eventual premarket approval (PMA) application.
newsfilecorp.com
2 months ago
White Bear Lake, Minnesota--(Newsfile Corp. - February 14, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on providing hearing loss sufferers with innovative solutions today announces additional patents for its growing patent portfolio. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat.
newsfilecorp.com
4 months ago
Initial patient enrollment anticipated during first quarter of 2025 White Bear Lake, Minnesota--(Newsfile Corp. - December 19, 2024) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company, today announces it has selected seven study sites for participation in its pivotal clinical trial to investigate its fully implanted Acclaim® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to begin during the first quarter of 2025.
globenewswire.com
5 months ago
FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company
globenewswire.com
5 months ago
Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant
globenewswire.com
5 months ago
WHITE BEAR LAKE, Minnesota, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No. 3858425, titled,” Implantable Modular Cochlear Implant System with Communication System and Network.”
See all news
